{"id":12817,"date":"2024-02-16T17:08:14","date_gmt":"2024-02-16T16:08:14","guid":{"rendered":"https:\/\/event.businessfrance.fr\/smart-manufacturing-summit-2024\/?p=12817"},"modified":"2024-03-04T17:05:59","modified_gmt":"2024-03-04T16:05:59","slug":"ctibiotech","status":"publish","type":"post","link":"https:\/\/event.businessfrance.fr\/smart-manufacturing-summit-2024\/ctibiotech\/","title":{"rendered":"CTIBIOTECH"},"content":{"rendered":"\n
<\/div>
<\/div><\/div>
\n
\"\"<\/div><\/div>
\n
CTIBIOTECH<\/strong>
<\/span><\/div>\n\n\n\n

<\/p>\n<\/div><\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n

\"\"<\/figure>\n\n\n\n
<\/div>
<\/div><\/div>
\n

about<\/mark> us :<\/mark><\/h2><\/div>\n\n\n\n

CTIBIOTECH\u2122 <\/strong>specializes in the production of human tissues using 3D bioprinting and additive manufacturing for biomedical, pharmaceutical, and dermato-cosmetic research and development. CTIBIOTECH\u2122 fosters innovative solutions for preclinical evaluation (efficacy and safety testing) of active ingredients, dermo-cosmetic products, therapeutic candidates, cell therapies, aesthetic devices, and medical devices. We industrialize the production of bioassays from biopsies collected with patient consent for medical, pharmaceutical and dermatocosmetics innovation.

CTIBIOTECH\u2122 has developed a biobank with capacity of 50 000 clinical samples in collaboration French and European hospitals from living donors that provided ethical informed consent. We mass-produce human skin models, tumor models containing the patient’s immune system, or human liver models enabling high value-added biomedical innovation. These unique industrial processes are based on 3D bioprinting, an additive manufacturing method that enables reproducible and precise production of patient-specific human tissues. We evaluate, for example, the response to anti-cancer drugs, the efficacy of a cosmetic product, treatments for burn victims or the safety of vaccines.

CTIBIOTECH\u2122 is looking for academic, industrial, financial and commercial partners to accelerate its technological developments in human tissue bioproduction (preclinical and clinical), with additive manufacturing, lab-on-chip, organ-on-chip in Japan and worldwide.<\/p><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

3D bioprinting of human tissue is an additive manufacturing method assembling human cells, biomaterials and nutrients to produce predictive 3D biological structure to accelerate biomedical, pharmaceutical and dermatocosmetics innovation.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

CTIBIOTECH is the first company in the world to produce human immunized skin by 3D Bioprinting technologies (Winner of H Maso Award 2022 IFSCC, Big Bang  L\u2019Oreal Asia Beauty Tech Award 2023) and now with a wide range of skin models used for dermatocosmetics, vaccine safety, medical device & pharmaceuticals evaluation.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

CTIBIOTECH developed state-of-the art additive manufacturing protocols for human tissue bioproduction with 3D bioprinting: tumors for cancer research and personalized medicine, complex skin tissues for preclinical and patients graft, liver for toxicology studies and cell therapies.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n